{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T05:04:46Z","timestamp":1789621486614,"version":"build-2803163510"},"reference-count":90,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Hypertension affects over 1.3 billion people worldwide, fewer than 20% achieve adequate blood pressure (BP) control. Poor long-term BP management accelerates irreversible damage to target organs, highlighting the urgent need for novel therapeutic approaches. Small interfering RNAs (siRNAs) are synthetic oligonucleotides that harness endogenous RNA interference machinery to silence specific disease-related genes with high sequence specificity, an approach that has opened new therapeutic avenues in cardiovascular medicine by enabling durable target modulation with infrequent dosing. N-acetylgalactosamine (GalNAc)-conjugated long-acting siRNA agents address two major limitations of oral antihypertensives: poor patient daily adherence and short-lived BP reduction. However, nearly all clinical candidates are designed to silence hepatic angiotensinogen (AGT). Single-target inhibition cannot fully overcome the compensatory signaling networks that drive primary hypertension, limiting protection against progressive target-organ damage. Existing reviews have largely summarized AGT-targeted RNA interference (RNAi) therapeutics. Rather than cataloguing individual agents, we propose a phenotype-matched framework that uses disease mechanisms to guide target selection, delivery strategies, and translational development toward precision RNAi therapy for hypertension. We review current clinical progress, examine the mechanistic basis of multi-pathway blockade, and discuss emerging molecular scaffolds for dual- and multi-target siRNA therapeutics. Finally, we discuss the major barriers to clinical translation\u2014including extrahepatic delivery, pharmacological reversibility, and safety considerations\u2014and identify the advances required for phenotype-guided RNAi therapies to move toward precision cardiovascular medicine. We emphasize that this phenotype-matched model is intended to generate hypotheses for target prioritization and validation, and does not represent a clinically established treatment strategy.<\/jats:p>","DOI":"10.3389\/fphar.2026.1943398","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T04:46:14Z","timestamp":1789620374000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-acting RNAi therapeutics in hypertension: limitations of single-target AGT silencing and rational multi-target synergistic strategies"],"prefix":"10.3389","volume":"17","author":[{"given":"Yi","family":"Lan","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical and Medical Devices, Ganzhou Dermatology Hospital","place":["Ganzhou, Jiangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxia","family":"Ye","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Ganzhou Dermatology Hospital","place":["Ganzhou, Jiangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingwei","family":"Zeng","sequence":"additional","affiliation":[{"name":"Third Inspection Office, Jiangxi Drug Inspection Center","place":["Nanchang, Jiangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenlong","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Medical Affairs, Guangzhou Xinhui Biotechnology Co., Ltd.","place":["Guangzhou, Guangdong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1161\/HYPERTENSIONAHA.122.19430","article-title":"Novel pharmacological approaches in the treatment of hypertension: a focus on RNA-based therapeutics","volume":"80","author":"Addison","year":"2023","journal-title":"Hypertension"},{"key":"B2","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1038\/s41587-019-0205-0","article-title":"A divalent siRNA chemical scaffold for potent and sustained modulation of gene expression throughout the central nervous system","volume":"37","author":"Alterman","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"6870","DOI":"10.1021\/acs.jmedchem.4c02528","article-title":"Metabolic stability and targeted delivery of oligonucleotides: advancing RNA therapeutics beyond the liver","volume":"68","author":"Anand","year":"2025","journal-title":"J. Med. Chem."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/S0140-6736(25)02064-1","article-title":"New drug therapies for hypertension","volume":"407","author":"Azizi","year":"2026","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1080\/14760584.2025.2508517","article-title":"Virus-like particles: a versatile and effective vaccine platform","volume":"24","author":"Bachmann","year":"2025","journal-title":"Expert Rev. Vaccines"},{"key":"B6","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1001\/jama.2024.0728","article-title":"RNA interference with Zilebesiran for mild to moderate hypertension: the KARDIA-1 randomized clinical trial","volume":"331","author":"Bakris","year":"2024","journal-title":"JAMA"},{"key":"B7","volume-title":"2025 Annual Report","year":"2026"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2855","DOI":"10.1161\/ATVBAHA.121.316290","article-title":"N-Acetyl galactosamine targeting: paving the way for clinical application of nucleotide medicines in cardiovascular diseases","volume":"41","author":"Biessen","year":"2021","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1161\/HYPERTENSIONAHA.110.158071","article-title":"Interleukin 6 knockout prevents angiotensin II hypertension: role of renal vasoconstriction and janus kinase 2\/signal transducer and activator of transcription 3 activation","volume":"56","author":"Brands","year":"2010","journal-title":"Hypertension"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1161\/01.hyp.27.4.1009","article-title":"Tumor necrosis factor activates angiotensinogen gene expression by the Rel A transactivator","volume":"27","author":"Brasier","year":"1996","journal-title":"Hypertension"},{"key":"B11","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1089\/nat.2019.0782","article-title":"Ligand conjugated multimeric siRNAs enable enhanced uptake and multiplexed gene silencing","volume":"29","author":"Brown","year":"2019","journal-title":"Nucleic Acid. Ther."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1161\/circresaha.118.313220","article-title":"Adherence in hypertension","volume":"124","author":"Burnier","year":"2019","journal-title":"Circ. Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1097\/01.hjh.0001115716.93531.61","article-title":"GLP-1RA, SGLT2I and raasi combination therapy reduces mortality and kidney events in patients with type 2 diabetes mellitus","volume":"43","author":"Casper","year":"2025","journal-title":"J. Hypertens."},{"key":"B14","doi-asserted-by":"publisher","first-page":"7929","DOI":"10.1073\/pnas.1200947109","article-title":"Activation of the renal Na+: Cl- cotransporter by angiotensin II is a WNK4-dependent process","volume":"109","author":"Casta\u00f1eda-Bueno","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B15","doi-asserted-by":"publisher","first-page":"100007","DOI":"10.59717\/j.xinn-drugdisc.2026.100007","article-title":"Therapeutic oligonucleotides revisited: focus on siRNA and antisense technologies","volume":"1","author":"Chen","year":"2026","journal-title":"Innovation Drug Discov."},{"key":"B16","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s12265-010-9169-7","article-title":"MicroRNA-21 in cardiovascular disease","volume":"3","author":"Cheng","year":"2010","journal-title":"J. Cardiovasc Transl. Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"14852","DOI":"10.1021\/acs.jmedchem.4c00802","article-title":"Structure-activity relationship of antibody-oligonucleotide conjugates: evaluating bioconjugation strategies for antibody-siRNA conjugates for drug development","volume":"67","author":"Cochran","year":"2024","journal-title":"J. Med. Chem."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1161\/HYPERTENSIONAHA.122.18731","article-title":"Angiotensinogen suppression: a new tool to treat cardiovascular and renal disease","volume":"79","author":"Cruz-L\u00f3pez","year":"2022","journal-title":"Hypertension"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e26638","DOI":"10.1161\/HYPERTENSIONAHA.125.26638","article-title":"High salt intake enhances the REVERSIR-induced recovery of blood pressure after angiotensinogen siRNA treatment","volume":"83","author":"Cruz-L\u00f3pez","year":"2026","journal-title":"Hypertension"},{"key":"B20","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa2208391","article-title":"Zilebesiran, an RNA interference therapeutic agent for hypertension","volume":"389","author":"Desai","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1001\/jama.2025.6681","article-title":"Add-On treatment with Zilebesiran for inadequately controlled hypertension: the KARDIA-2 randomized clinical trial","volume":"334","author":"Desai","year":"2025","journal-title":"JAMA"},{"key":"B22","doi-asserted-by":"publisher","first-page":"115386","DOI":"10.1016\/j.bcp.2022.115386","article-title":"Renal sympathetic activity: a key modulator of pressure natriuresis in hypertension","volume":"208","author":"D\u00edaz-Morales","year":"2023","journal-title":"Biochem. Pharmacol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1152\/physrev.1997.77.1.75","article-title":"Neural control of renal function","volume":"77","author":"DiBona","year":"1997","journal-title":"Physiol. Rev."},{"key":"B24","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/s41577-019-0160-5","article-title":"Immune mechanisms of hypertension","volume":"19","author":"Drummond","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1093\/nar\/gkad067","article-title":"Chemistry, structure and function of approved oligonucleotide therapeutics","volume":"51","author":"Egli","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","article-title":"Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis","volume":"387","author":"Ettehad","year":"2016","journal-title":"Lancet"},{"key":"B27","doi-asserted-by":"publisher","first-page":"216","DOI":"10.3390\/clinpract15110216","article-title":"Contribution of final-year medical students to hypertension diagnosis in primary care units","volume":"15","author":"Evangelidis","year":"2025","journal-title":"Clin. Pract."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1152\/physrev.00035.2024","article-title":"Central nervous system mechanisms of salt-sensitive hypertension","volume":"105","author":"Feng","year":"2025","journal-title":"Physiol. Rev."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1786728","DOI":"10.3389\/fphar.2026.1786728","article-title":"Comparative efficacy and safety of dual-combination vs. triple-combination antihypertensive therapies in hypertensive patients: an updated meta-analysis of randomized controlled trials","volume":"17","author":"Gong","year":"2026","journal-title":"Front. Pharmacol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/s41569-023-00964-1","article-title":"Immune and inflammatory mechanisms in hypertension","volume":"21","author":"Guzik","year":"2024","journal-title":"Nat. Rev. Cardiol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/s41581-019-0145-4","article-title":"Obesity, kidney dysfunction and hypertension: mechanistic links","volume":"15","author":"Hall","year":"2019","journal-title":"Nat. Rev. Nephrol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1161\/CIRCRESAHA.121.318082","article-title":"Pathophysiology of hypertension: the mosaic theory and beyond","volume":"128","author":"Harrison","year":"2021","journal-title":"Circ. Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1152\/physrev.00044.2018","article-title":"Regulation of the renal NaCl cotransporter and its role in potassium homeostasis","volume":"100","author":"Hoorn","year":"2020","journal-title":"Physiol. Rev."},{"key":"B34","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s11658-023-00423-2","article-title":"Endothelial dysfunction due to eNOS uncoupling: molecular mechanisms as potential therapeutic targets","volume":"28","author":"Janaszak-Jasiecka","year":"2023","journal-title":"Cell Mol. Biol. Lett."},{"key":"B35","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jconrel.2021.11.009","article-title":"Protein-RNA interaction guided chemical modification of Dicer substrate RNA nanostructures for superior in vivo gene silencing","volume":"343","author":"Jang","year":"2022","journal-title":"J. Control Release"},{"key":"B36","doi-asserted-by":"publisher","first-page":"e26091","DOI":"10.1161\/HYPERTENSIONAHA.125.26091","article-title":"Angiotensinogen reconsidered: evolving perspectives in hypertension research","volume":"83","author":"Kanbay","year":"2026","journal-title":"Hypertension"},{"key":"B37","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1210\/jcem.83.11.5276","article-title":"Human adipose tissue expresses angiotensinogen and enzymes required for its conversion to angiotensin II","volume":"83","author":"Karlsson","year":"1998","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B38","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nbt1051","article-title":"Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy","volume":"23","author":"Kim","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"3908","DOI":"10.1039\/d5sc02211h","article-title":"Virus-like particles based on plant viruses and bacteriophages: emerging strategies for the delivery of nucleic acid therapeutics","volume":"17","author":"Kim","year":"2026","journal-title":"Chem. Sci."},{"key":"B40","doi-asserted-by":"publisher","first-page":"e00258","DOI":"10.1161\/HYP.0000000000000258","article-title":"Single-Pill combination therapy for the management of hypertension: a scientific statement from the American heart association","volume":"83","author":"King","year":"2026","journal-title":"Hypertension"},{"key":"B41","doi-asserted-by":"publisher","first-page":"4582","DOI":"10.1021\/acsnano.4c14675","article-title":"Engineered extracellular vesicles modified by Angiopep-2 peptide promote targeted repair of spinal cord injury and brain inflammation","volume":"19","author":"Kong","year":"2025","journal-title":"ACS Nano"},{"key":"B42","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1093\/eurheartj\/ehac395","article-title":"Hypertension management in patients with cardiovascular comorbidities","volume":"44","author":"Lauder","year":"2023","journal-title":"Eur. Heart J."},{"key":"B43","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.phrs.2017.07.026","article-title":"Antihypertensive drugs","volume":"124","author":"Laurent","year":"2017","journal-title":"Pharmacol. Res."},{"key":"B44","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1161\/ATVBAHA.119.311904","article-title":"How do SGLT2 (sodium-glucose cotransporter 2) inhibitors and GLP-1 (glucagon-like peptide-1) receptor agonists reduce cardiovascular outcomes? completed and ongoing mechanistic trials","volume":"40","author":"Lee","year":"2020","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1093\/nar\/gkn109","article-title":"Inhibition of HIV-1 by multiple siRNAs expressed from a single microRNA polycistron","volume":"36","author":"Liu","year":"2008","journal-title":"Nucleic Acids Res."},{"key":"B46","doi-asserted-by":"publisher","first-page":"e2525726123","DOI":"10.1073\/pnas.2525726123","article-title":"Humanized extracellular vesicles for efficient RNA delivery","volume":"123","author":"Ma","year":"2026","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","article-title":"2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA)","volume":"41","author":"Mancia","year":"2023","journal-title":"J. Hypertens."},{"key":"B48","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1161\/HYPERTENSIONAHA.120.14868","article-title":"Endogenous activation of glucagon-like peptide-1 receptor contributes to blood pressure control: role of proximal tubule Na+\/H+ exchanger isoform 3, renal angiotensin II, and insulin sensitivity","volume":"76","author":"Martins","year":"2020","journal-title":"Hypertension"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1021\/acschembio.4c00290","article-title":"In vivo injection of reversible optically controlled short interfering RNA into Japanese medaka embryos (Oryzias latipes) to regulate gene silencing","volume":"19","author":"Mateus","year":"2024","journal-title":"ACS Chem. Biol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"10717","DOI":"10.3390\/ijms262110717","article-title":"Zilebesiran as an innovative siRNA-based therapeutic approach for hypertension: emerging perspectives in cardiovascular medicine","volume":"26","author":"Morosan","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"B51","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S0140-6736(21)01330-1","article-title":"Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants","volume":"398","year":"2021","journal-title":"Lancet"},{"key":"B52","doi-asserted-by":"publisher","first-page":"103146","DOI":"10.1016\/j.arr.2026.103146","article-title":"The role and mechanisms of methylation modifications in the development and progression of hypertension","volume":"118","author":"Niu","year":"2026","journal-title":"Ageing Res. Rev."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.3390\/medicina60101668","article-title":"Exploring adiposity and chronic kidney disease: clinical implications, management strategies, prognostic considerations","volume":"60","author":"Ozbek","year":"2024","journal-title":"Medicina (Kaunas)"},{"key":"B54","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/nrcardio.2013.1","article-title":"Assessment and management of blood-pressure variability","volume":"10","author":"Parati","year":"2013","journal-title":"Nat. Rev. Cardiol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1152\/physrev.00036.2005","article-title":"Physiology of local renin-angiotensin systems","volume":"86","author":"Paul","year":"2006","journal-title":"Physiol. Rev."},{"key":"B56","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41576-021-00439-4","article-title":"Drug delivery systems for RNA therapeutics","volume":"23","author":"Paunovska","year":"2022","journal-title":"Nat. Rev. Genet."},{"key":"B57","doi-asserted-by":"publisher","first-page":"148","DOI":"10.3390\/v17020148","article-title":"The role of plant virus-like particles in advanced drug delivery and vaccine development: structural attributes and application potential","volume":"17","author":"Peralta-Cuevas","year":"2025","journal-title":"Viruses"},{"key":"B58","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/s41581-021-00414-6","article-title":"The evolving complexity of the collecting duct renin-angiotensin system in hypertension","volume":"17","author":"Prieto","year":"2021","journal-title":"Nat. Rev. Nephrol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"738848","DOI":"10.3389\/fendo.2021.738848","article-title":"Effects of SGLT2 inhibitors and GLP-1 receptor agonists on renin-angiotensin-aldosterone system","volume":"12","author":"Puglisi","year":"2021","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"B60","doi-asserted-by":"publisher","first-page":"F931","DOI":"10.1152\/ajprenal.00367.2014","article-title":"Collecting duct-specific knockout of renin attenuates angiotensin II-induced hypertension","volume":"307","author":"Ramkumar","year":"2014","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.1111\/bph.15972","article-title":"Small interfering RNA: discovery, pharmacology and clinical development-An introductory review","volume":"180","author":"Ranasinghe","year":"2023","journal-title":"Br. J. Pharmacol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s11906-025-01325-8","article-title":"Small interfering RNA therapy for the management and prevention of hypertension","volume":"27","author":"Ren","year":"2025","journal-title":"Curr. Hypertens. Rep."},{"key":"B63","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","article-title":"Advances in oligonucleotide drug delivery","volume":"19","author":"Roberts","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"B64","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1161\/HYPERTENSIONAHA.119.13642","article-title":"Effects of Interleukin-1\u03b2 inhibition on blood pressure, incident hypertension, and residual inflammatory risk: a secondary analysis of CANTOS","volume":"75","author":"Rothman","year":"2020","journal-title":"Hypertension"},{"key":"B65","unstructured":"SAL0132 phase I study data\n          \n          \n          2026"},{"key":"B66","doi-asserted-by":"publisher","first-page":"4384","DOI":"10.1073\/pnas.0813238106","article-title":"Angiotensin II signaling increases activity of the renal Na-Cl cotransporter through a WNK4-SPAK-dependent pathway","volume":"106","author":"San-Cristobal","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B67","unstructured":"SGB-3908 phase I study results\n          \n          \n          2025"},{"key":"B68","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/s11906-018-0900-0","article-title":"Inflammation as a regulator of the renin-angiotensin system and blood pressure","volume":"20","author":"Satou","year":"2018","journal-title":"Curr. Hypertens. Rep."},{"key":"B69","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/s41574-019-0230-6","article-title":"The endocrine function of adipose tissues in health and cardiometabolic disease","volume":"15","author":"Scheja","year":"2019","journal-title":"Nat. Rev. Endocrinol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"e0165703","DOI":"10.1371\/journal.pone.0165703","article-title":"Effect of sodium-glucose co-transporter 2 inhibitor, dapagliflozin, on renal renin-angiotensin system in an animal model of type 2 diabetes","volume":"11","author":"Shin","year":"2016","journal-title":"PLoS One"},{"key":"B71","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s11906-025-01342-7","article-title":"Blood pressure-lowering effects of SGLT2 inhibitors and GLP-1 receptor agonists","volume":"27","author":"Siddiqi","year":"2025","journal-title":"Curr. Hypertens. Rep."},{"key":"B72","volume-title":"2024 Annual Report","year":"2025"},{"key":"B73","doi-asserted-by":"publisher","first-page":"E664","DOI":"10.1210\/jc.2012-3855","article-title":"Glucagon-like peptide-1 (GLP-1): effect on kidney hemodynamics and renin-angiotensin-aldosterone system in healthy men","volume":"98","author":"Skov","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B74","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1161\/HYPERTENSIONAHA.116.07747","article-title":"Astrocytes contribute to angiotensin II stimulation of hypothalamic neuronal activity and sympathetic outflow","volume":"68","author":"Stern","year":"2016","journal-title":"Hypertension"},{"key":"B75","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/s41581-025-01020-6","article-title":"The genetics of hypertension","volume":"22","author":"St\u00f6lting","year":"2026","journal-title":"Nat. Rev. Nephrol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41573-024-00912-9","article-title":"RNAi-based drug design: considerations and future directions","volume":"23","author":"Tang","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"B77","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1161\/HYPERTENSIONAHA.119.12703","article-title":"Strong and sustained antihypertensive effect of small interfering RNA targeting liver angiotensinogen","volume":"73","author":"Uijl","year":"2019","journal-title":"Hypertension"},{"key":"B78","doi-asserted-by":"publisher","first-page":"e026426","DOI":"10.1161\/JAHA.122.026426","article-title":"Conventional vasopressor and vasopressor-sparing strategies to counteract the blood pressure-lowering effect of small interfering RNA targeting angiotensinogen","volume":"11","author":"Uijl","year":"2022","journal-title":"J. Am. Heart Assoc."},{"key":"B79","doi-asserted-by":"publisher","first-page":"C2013","DOI":"10.1152\/ajpcell.00587.2025","article-title":"Emerging roles of astrocytes in autonomic control of blood pressure and hypertension","volume":"329","author":"Verma","year":"2025","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1161\/HYPERTENSIONAHA.125.24002","article-title":"Is it time to abandon the kidney-centered view on the origin of primary hypertension?","volume":"82","author":"Vogt","year":"2025","journal-title":"Hypertension"},{"key":"B81","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41596-022-00755-x","article-title":"Preparation of selective organ-targeting (SORT) lipid nanoparticles (LNPs) using multiple technical methods for tissue-specific mRNA delivery","volume":"18","author":"Wang","year":"2023","journal-title":"Nat. Protoc."},{"key":"B82","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1161\/CIRCULATIONAHA.126.079538","article-title":"The 2026 American cCollege of Cardiology\/American Heart Association Multisociety Guideline on the management of dyslipidemia: a more precise-but more complicated-framework for atherosclerotic cardiovascular disease prevention and treatment","volume":"153","author":"Watson","year":"2026","journal-title":"Circulation"},{"key":"B83","volume-title":"Guideline for the Pharmacological Treatment of Hypertension in Adults","year":"2021"},{"key":"B84","volume-title":"Global Report on Hypertension: The Race Against a Silent Killer","year":"2023"},{"key":"B85","doi-asserted-by":"publisher","first-page":"e114","DOI":"10.1161\/CIR.0000000000001356","article-title":"AHA\/ACC\/AANP\/AAPA\/ABC\/ACCP\/ACPM\/AGS\/AMA\/ASPC\/NMA\/PCNA\/SGIM guideline for the prevention, detection, evaluation and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"152","author":"Jones","year":"2025","journal-title":"Circulation"},{"key":"B86","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1161\/ATVBAHA.123.319897","article-title":"Targeting angiotensinogen with N-acetylgalactosamine-conjugated small interfering RNA to reduce blood pressure","volume":"43","author":"Ye","year":"2023","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1161\/HYPERTENSIONAHA.124.22878","article-title":"Counteracting angiotensinogen small-interfering RNA-mediated antihypertensive effects with REVERSIR","volume":"81","author":"Ye","year":"2024","journal-title":"Hypertension"},{"key":"B88","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s12012-013-9219-x","article-title":"Interaction between AT1 receptor and NF-\u03baB in hypothalamic paraventricular nucleus contributes to oxidative stress and sympathoexcitation by modulating neurotransmitters in heart failure","volume":"13","author":"Yu","year":"2013","journal-title":"Cardiovasc Toxicol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/s41440-020-00553-6","article-title":"MiRNAs, lncRNAs, and circular RNAs as mediators in hypertension-related vascular smooth muscle cell dysfunction","volume":"44","author":"Zhang","year":"2021","journal-title":"Hypertens. Res."},{"key":"B90","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/nbt.4136","article-title":"Reversal of siRNA-mediated gene silencing in vivo","volume":"36","author":"Zlatev","year":"2018","journal-title":"Nat. Biotechnol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1943398\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T04:46:28Z","timestamp":1789620388000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1943398\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":90,"alternative-id":["10.3389\/fphar.2026.1943398"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1943398","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,17]]},"article-number":"1943398"}}